Paid Clinical Trials Fresno

Discover 201 paid clinical trials in Fresno, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 201

Remibrutinib vs. TeriflunomideEfficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting

PHASE3

Sponsor:

Novartis Pharmaceuticals

Location:

Hanford CA, West Hollywood CA, Los Angeles CA, Phoenix AZshow 59 more

Code:

NCT05156281

Conditions

Relapsing Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Remibrutinib

Teriflunomide

Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Fresno CA, Merced CA, Modesto CA, Salinas CAshow 715 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

Lenalidomide & DaratumumabS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Recruiting

PHASE3

Sponsor:

SWOG Cancer Research Network

Location:

Fresno CA, Merced CA, Modesto CA, San Luis Obispo CAshow 530 more

Code:

NCT04071457

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Lenalidomide

Daratumumab/rHuPH20

SeralutinibEfficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Recruiting

PHASE3

Sponsor:

GB002, Inc.

Location:

Fresno CA, Stanford CA, Sacramento CA, Santa Barbara CAshow 51 more

Code:

NCT05934526

Conditions

Pulmonary Arterial Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Placebo

Seralutinib

Generic Dry Powder Inhaler

Nivolumab, Ipilimumab, CabozantinibTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Clovis CA, San Luis Obispo CA, Arroyo Grande CA, Santa Maria CAshow 368 more

Code:

NCT03866382

Conditions

Bladder Adenocarcinoma

Bladder Clear Cell Adenocarcinoma

Bladder Mixed Adenocarcinoma

Bladder Neuroendocrine Carcinoma

Bladder Small Cell Neuroendocrine Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Scan

Cabozantinib S-malate

Computed Tomography

Echocardiography Test

Zanubrutinib & Anti-CD20A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Recruiting

PHASE3

Sponsor:

BeiGene

Location:

Fresno CA, Los Angeles CA, Los Alamitos CA, Irvine CAshow 58 more

Code:

NCT05100862

Conditions

Relapsed/Refractory Follicular Lymphoma

Marginal Zone Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Zanubrutinib

Rituximab

Lenalidomide

Obinutuzumab

Zongertinib vs. Standard TreatmentBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Recruiting

PHASE3

Sponsor:

Boehringer Ingelheim

Location:

Fresno CA, Reno NV, Glendale CA, Beverly Hills CAshow 17 more

Code:

NCT06151574

Conditions

Lung Cancer, Non-squamous, Non-small Cell

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

zongertinib

pembrolizumab

cisplatin

carboplatin

pemetrexed

Glofitamab & Polatuzumab VedotinAn Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Recruiting

PHASE3

Sponsor:

Hoffmann-La Roche

Location:

Clovis CA, Santa Clara CA, Stanford CA, Walnut Creek CAshow 76 more

Code:

NCT06047080

Conditions

Large B-Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Glofitamab

Polatuzumab vedotin

Rituximab

Cyclophosphamide

Doxorubicin

AvacopanA Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Recruiting

Sponsor:

Amgen

Location:

Fresno CA, Fremont CA, Reno NV, Covina CAshow 33 more

Code:

NCT06072482

Conditions

Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Avacopan

Placebo

Standard of Care

Belinostat & PralatrexateTo Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting

PHASE3

Sponsor:

Acrotech Biopharma Inc.

Location:

Clovis CA, Los Angeles CA, Temple TX, Houston TXshow 4 more

Code:

NCT06072131

Conditions

Peripheral T Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Belinostat Injection

Pralatrexate Injection

CHOP

COP